In vitro preclinical services
Validate new molecules and secure your next go-to in vivo step with our CRO
Using our in vitro models, we assess new leads from your libraries by testing their nephrotoxicity and efficacy (on selected parameters) within a month.
Exploration of molecular mechanisms or in vivo validation are guided by Go/No-Go decisions.
Characteristics of our innovative solutions :
- Shows >80% of physiological features
- High level of drug effects prediction
- Modulable micro-environment
- Reduction of animal tests failures and costs
Cell types
Podocytes
Mesangial
Tubular cells (proximal, TAL, distal)
Endothelial
Fibroblasts
more ...
Environment
Inflammatory
Hyperglycemic
Fibrotic
Hypoxic
Drug toxicity
more ...
Parameters
Cell death &
membrane leakage
Epithelium integrity
Mitochondrial activity
Gene & Protein expression
Channel & transporter function
more ...
Our popular tests
The in vitro Fibrosis Assay allows controlled, ethical study of scar tissue formation and drug effects, providing predictive and quantitative insights for preclinical research.
Read more about our fibrosis assay…
The in vitro inflammation assay enables controlled testing of inflammatory responses and potential anti-inflammatory drugs for predictive preclinical research.
Read more about our inflammation assay…
Why Choose Nephrix Biosolutions?
Scientific Expertise – From cell culture to detailed in vitro assay analysis.
Predictive Preclinical Models – Tailored workflows for your unique samples and study goals.
Flexible and Customizable Services – Quantitative, reproducible, and objective results.
Dedicated Support – Streamlined for in vivo preclinical research timelines.
Why Choose Nephrix Biosolutions?
Scientific Expertise – From cell culture to detailed in vitro assay analysis.
Predictive Preclinical Models – Tailored workflows for your unique samples and study goals.
Flexible and Customizable Services – Quantitative, reproducible, and objective results.
Dedicated Support – Streamlined for in vivo preclinical research timelines.